Your browser is no longer supported. Please, upgrade your browser.
NVUS Novus Therapeutics, Inc. daily Stock Chart
Novus Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.94 Insider Own29.76% Shs Outstand6.80M Perf Week-1.29%
Market Cap26.04M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.98M Perf Month-7.93%
Income-14.70M PEG- EPS next Q- Inst Own53.20% Short Float0.80% Perf Quarter-12.16%
Sales- P/S- EPS this Y16.40% Inst Trans- Short Ratio4.10 Perf Half Y-31.73%
Book/sh2.97 P/B1.29 EPS next Y- ROA-55.90% Target Price18.00 Perf Year-59.08%
Cash/sh- P/C- EPS next 5Y- ROE-62.50% 52W Range3.42 - 9.36 Perf YTD-5.67%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-58.55% Beta0.84
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low13.45% ATR0.24
Employees8 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)48.07 Volatility5.76% 6.03%
OptionableNo Debt/Eq0.00 EPS Q/Q88.40% Profit Margin- Rel Volume1.04 Prev Close3.83
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume9.70K Price3.88
Recom3.00 SMA20-2.10% SMA50-3.79% SMA200-18.79% Volume7,559 Change1.31%
Jan-05-18 07:20PM  Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)? Simply Wall St.
Nov-21-17 03:00PM  Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
12:49PM  Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)? Simply Wall St.
Nov-08-17 04:52PM  Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire
Nov-06-17 04:01PM  Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President PR Newswire -6.56%
Oct-05-17 09:26AM  Whats The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)? Simply Wall St.
Aug-09-17 06:08PM  Novus Therapeutics Reports Second Quarter 2017 Results PR Newswire
Jul-10-17 06:30AM  Novus Therapeutics Announces Change in Management PR Newswire
Jun-12-17 08:00AM  Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Otic Pharma Ltd. manufactures foam drug delivery system to treat ear disorders. The company was founded in 2008 and is based in Or-Yehuda, Israel.